Neonatal Screening for Spinal Muscular Atrophy and Severe T- and B-Cell Lymphopenias in Andalusia: A Prospective Study

Spinal muscular atrophy (SMA) and severe T- and/or B-cell lymphopenias (STBCL) in the form of severe combined immunodeficiencies (SCID) or X-linked agammaglobulinemia (XLA) are rare but potentially fatal pathologies. In January 2021, we initiated the first pilot study in Spain to evaluate the effica...

Descripción completa

Detalles Bibliográficos
Autores: Felipe, Beatriz de, Delgado-Pecellín, Isabel, López Lobato, Mercedes, Olbrich, Peter, Blanco Lobo, Pilar, Márquez Fernández, Josefina, Salamanca, Carmen, Mendoza, Beatriz, Castro Serrano, Rocío, Duque, Cristina, Moreno Prieto, Mariana, Madruga-Garrido, Marcos, Lucena, Jose M., Fernández, Raquel M., Ruiz Camacho, María, Varona, Alberto, Neth, Olaf
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/390750
Acceso en línea:http://hdl.handle.net/10261/390750
https://api.elsevier.com/content/abstract/scopus_id/105002007285
Access Level:acceso abierto
Palabra clave:KRECs
SCID
SMA
TRECs
Newborn screening
Spinal muscular atrophy
Descripción
Sumario:Spinal muscular atrophy (SMA) and severe T- and/or B-cell lymphopenias (STBCL) in the form of severe combined immunodeficiencies (SCID) or X-linked agammaglobulinemia (XLA) are rare but potentially fatal pathologies. In January 2021, we initiated the first pilot study in Spain to evaluate the efficacy of a very early detection technique for SMA and SCID. RT-PCR was performed on prospectively collected dried blood spots (DBSs) from newborns in Western Andalusia (Spain). Internal and external controls (SCID, XLA and SMA) were included. The determination of SMA was relative (positive/negative) and that of TRECs and KRECs was quantitative (copies/punch). A total of 14.035 prospective samples were analysed. All controls were correctly identified while no cases of SMA or SCID/XLA were prospectively identified. DBS analysis of infants with suspected SMA or STBCL that presented to our centre showed pathological values in two cases each for SMA and SCID and one for XLA, all of them being subsequently confirmed genetically. In this prospective pilot study, no infants with SMA or STBCL were detected; however, the technique applied here was shown to be reliable and fast, further supporting the benefits and need to include SMA and SCID in national newborn screening (NBS) programs, as it will allow early supportive and curative therapy.

Similares en LA Referencia